<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11076648</article-id><article-id pub-id-type="pmc">2363412</article-id><article-id pub-id-type="pii">6691508</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1508</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chin</surname><given-names>K-F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Greenman</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gardiner</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Topping</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Monson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Academic Surgical Unit and Department of Mathematics, <label>2</label>Department of Mathematics, The University of Hull, Hull, UK</aff><pub-date pub-type="epub"><day>22</day><month>11</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>83</volume><issue>11</issue><fpage>1425</fpage><lpage>1431</lpage><history><date date-type="received"><day>30</day><month>11</month><year>1999</year></date><date date-type="rev-recd"><day>03</day><month>08</month><year>2000</year></date><date date-type="accepted"><day>15</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We aim to determine the clinical usefulness of pre-operative serum vascular endothelial growth factor (VEGF) as a predictor of outcome in patients undergoing curative resection for colorectal cancer. Serum VEGF was assayed by quantitative ELISA in 81 patients prior to curative resection for node-negative (n = 53) and node-positive (n = 28) disease. Median follow-up for patients without cancer death was 27 months (range 21&#x02013;37). Pre-operative serum VEGF was significantly higher in patients who went on to develop metastases than those who did not (median, 713 pg ml&#x02013;1 vs. 314 pg ml&#x02013;1, P &#x0003c; 0.0001). Using multivariate Cox regression analysis, pre-operative serum VEGF was the most important prognostic factor independent of nodal status and adjuvant chemotherapy, and was superior to nodal status in predicting outcome (P &#x0003c; 0.00001). At 575 pg ml&#x02013;1, pre-operative serum VEGF was 64&#x00025; sensitive and 89&#x00025; specific in predicting the development of metastases in curative resections, with a positive predictive value of 73&#x00025; and a negative predictive value of 85&#x00025;. Pre-operative serum VEGF is a powerful predictor of outcome following curative surgery for colorectal cancer. These data support the measurement of pre-operative serum VEGF as a method for selecting patients who require adjuvant therapy. &#x000a9; 2000 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>vascular endothelial growth factor</kwd><kwd>tumour marker</kwd><kwd>colorectal cancer</kwd></kwd-group></article-meta></front></article>


